Analyst Ratings — November 18, 2026 — Midday Update — Last 24 Hours (Pacific Time)
Executive Summary
Analyst activity over the past 24 hours was dominated by Nvidia coverage following what appears to be a significant earnings or guidance event, with over a dozen firms weighing in — the majority bullish but with notable price target cuts tied to CEO transition uncertainty and longer-term growth concerns. Walt Disney also drew a wave of price target raises across multiple firms after an earnings beat, while Nike's post-Investor Day reception was decidedly mixed-to-bearish. The most active firms were JPMorgan, BMO Capital, Truist Securities, Guggenheim, and Piper Sandler, with themes of AI monetization, margin pressure, and leadership uncertainty driving the bulk of the action.
Analyst Action Breakdown
| Action Type | Count | Percentage |
|---|---|---|
| Upgrades | 10 | ~6% |
| Downgrades | 13 | ~8% |
| PT Raises | 42 | ~25% |
| PT Cuts | 37 | ~22% |
| Reiterations (no PT change) | 54 | ~32% |
| Initiations | 7 | ~4% |
| PT Raises + Reiteration (combined) | ~12 | ~7% |
Net Sentiment: 🟡 Mixed — leaning cautiously Bullish
While upgrades slightly trail downgrades in raw count, the volume of price target raises meaningfully outpaces cuts, and the majority of reiterations carry Buy/Outperform/Overweight ratings. The bearish signals are concentrated in specific names (Nvidia PT cuts on CEO uncertainty, Nike, Klarna, Home Depot) rather than broad-based, suggesting selective rather than systemic concern.
Top Analyst Calls
🟢 JPMorgan → Nvidia (NVDA) — Raised PT to $230 from $215, maintains Overweight
- Strong quarterly guidance drove the raise, even as other firms trimmed targets on leadership uncertainty.
🟢 Wedbush → Nvidia (NVDA) — Raised PT to $293 from $275, reiterates Outperform
- Analyst Dan Ives cited strong demand outlook following Nvidia's recent results as justification for the Street's highest published target in this cycle.
🔴 Summit Insights → Nvidia (NVDA) — Downgraded to Hold from Buy
- Firm cited uncertainty created by a leadership transition as the primary reason for the downgrade.
🔴 Piper Sandler → Nvidia (NVDA) — Cut PT to $230 from $300, maintains Overweight
- CEO uncertainty drove the significant $70 price target reduction despite the firm holding its bullish rating.
🟢 Argus → Elevance Health (ELV) — Upgraded to Buy from Hold, PT $510
- Firm cited a positive 2027 growth outlook as the catalyst for the upgrade.
🟢 Raymond James → Charles Schwab (SCHW) — Upgraded to Strong Buy from Outperform
- Favorable interest rate outlook underpinned the upgrade to the firm's highest conviction rating.
🟢 Piper Sandler → AbbVie (ABBV) — Raised PT to $349 from $303, maintains Overweight
- A $46 price target increase driven by growth prospects makes this one of the largest magnitude raises of the session.
🟢 Piper Sandler → Instacart (CART) — Raised PT to $65 from $50, maintains Overweight
- A DoorDash-related deal drove a $15 price target increase.
🔴 Stifel → Insulet (PODD) — Downgraded to Hold from Buy, PT cut to $165
- U.S. momentum concerns prompted the downgrade, directly contrasting with Jefferies' same-day Buy reiteration at $200.
🔴 BofA → Enovix (ENVX) — Downgraded to Underperform from Neutral, PT cut to $1
- A strategy shift at the company drove BofA to its most bearish rating, with a dramatic price target reduction.
🟢 Guggenheim → Walt Disney (DIS) — Raised PT to $135 from $120, maintains Buy
- An earnings beat drove the raise; multiple firms (JPMorgan, Wells Fargo, Rosenblatt, Raymond James, Needham, StoneX) also raised targets on Disney in the same session.
🔴 JPMorgan → Alnylam Pharmaceuticals (ALNY) — Cut PT to $254 from $369, maintains Overweight
- A revised Amvuttra forecast drove one of the largest absolute dollar PT cuts of the session (-$115).
🟢 TD Cowen → Royalty Pharma (RPRX) — Raised PT to $80 from $68, maintains Buy
- A positive growth outlook supported the $12 price target increase.
🔴 Erste Group → GE Vernova (GEV), Eaton (ETN), Freeport-McMoRan (FCX) — All downgraded to Hold from Buy
- Erste Group issued a trio of downgrades citing slower 2027 order outlook, rising debt, and production declines respectively.
🟢 UBS → SOLV Energy (MWH) — Upgraded to Buy from Neutral, PT $37
- Strong backlog growth drove the upgrade for the solar energy installer.
Firm Activity Summary
JPMorgan — 10 calls (5 bullish, 4 bearish, 1 neutral)
- NVDA (PT raise), MSFT (reiterate Buy), DIS (PT raise), NKE (PT raise, Underweight), ALNY (PT cut), KLAR (PT cut), VIK (PT cut), HD (PT cut), SCHW (upgrade via Raymond James — note: this was Raymond James), TIGO (upgrade), MANH (initiation Overweight), ADNOCDRILL (downgrade)
BMO Capital — 8 calls (4 bullish, 2 bearish, 2 neutral)
- TTWO (reiterate Outperform), NVDA (reiterate Outperform), NKE (reiterate Underperform), KLAR (PT cut), BILL (PT raise), BL (PT cut), BTSG (PT raise), MHHE (reiterate Outperform)
Truist Securities — 10 calls (6 bullish, 2 bearish, 2 neutral)
- TDOC (PT raise), GXO (PT raise), GLBE (reiterate Buy), AGL (reiterate Hold), TGT (reiterate Outperform), HD (PT raise), TYL (PT raise), CHRD (reiterate Buy), NVDA (reiterate Hold), NKE (reiterate Sell), LOW (reiterate Buy), DLO (PT cut), BALY (PT cut), LUCK (downgrade)
Guggenheim — 7 calls (5 bullish, 2 bearish)
- MSFT (reiterate Buy), DIS (PT raise), GHRS (PT raise), BROS (PT cut), IONS (PT cut), GTN (PT raise), SBGI (PT raise)
Piper Sandler — 6 calls (4 bullish, 1 bearish, 1 neutral)
- MSFT (reiterate Overweight), TTAN (reiterate Overweight), ABBV (PT raise), CART (PT raise), NKE (reiterate Neutral), NVDA (PT cut), INVA (initiation Overweight)
Jefferies — 5 calls (3 bullish, 1 neutral, 1 bearish)
- PODD (reiterate Buy), SHC (reiterate Buy), PGR (reiterate Hold), HASI (PT raise), NVDA (PT cut), ARDX (reiterate Buy)
Mizuho — 6 calls (3 bullish, 3 bearish)
- NVDA (reiterate Outperform), MSFT (reiterate Outperform), SR (PT raise), JD (PT cut), TME (PT cut), HD (PT cut)
Morgan Stanley — 7 calls (2 bullish, 4 bearish, 1 neutral)
- ENR (PT raise), VIK (PT raise), KLAR (PT cut), DCH (PT cut), NVDA (PT cut), CRK (downgrade), CNX (upgrade), LLESY (downgrade)
Wells Fargo — 4 calls (3 bullish, 1 bearish)
- VIK (PT raise), DIS (PT raise), PG (PT raise), NVDA (PT cut)
B.Riley — 7 calls (5 bullish, 1 bearish, 1 neutral)
- TTWO (reiterate Buy), CLYM (reiterate Buy), CUE (PT cut), OPRA (PT cut), HYPR (PT cut), SECZ (initiation Buy), CHYM (PT raise)
TD Cowen — 5 calls (4 bullish, 1 neutral)
- GILD (reiterate Buy), RPRX (PT raise), TYL (PT raise), NVDA (reiterate Buy), MSFT (reiterate Buy), HSY (reiterate Hold)
RBC Capital — 5 calls (4 bullish, 1 neutral)
- MU (reiterate Outperform), HD (PT cut), FANG (reiterate Outperform), CLYM (reiterate Outperform), SNMCY (initiation Outperform)
Erste Group — 4 calls (1 bullish, 3 bearish)
- XOM (upgrade to Buy), ETN (downgrade), FCX (downgrade), GEV (downgrade)
Oppenheimer — 5 calls (4 bullish, 0 bearish, 1 neutral)
- TTWO (reiterate Outperform), MSFT (reiterate Outperform), ACAD (PT cut), MIDD (reiterate Outperform), MFP (reiterate Outperform), SMWB (PT raise)
Stifel — 5 calls (3 bullish, 2 bearish)
- TNDM (upgrade to Buy), PODD (downgrade), ECL (PT raise), NKE (reiterate Hold), NVDA (reiterate Buy), BAER (downgrade)
KeyBanc — 3 calls (2 bullish, 1 neutral)
- MCD (reiterate Overweight), ACM (PT raise), ONEW (reiterate Overweight)
Needham — 4 calls (2 bullish, 2 neutral)
- NKE (reiterate Hold), BIIB (reiterate Buy), DIS (PT raise), NVDA (reiterate Buy)
UBS — 3 calls (2 bullish, 1 bearish)
- SNOW (PT cut), NVDA (PT cut), MWH (upgrade to Buy)
Susquehanna — 2 calls (1 bullish, 1 bearish)
- NVDA (reiterate Positive), BIDU (PT cut)
Keefe Bruyette — 3 calls (0 bullish, 3 bearish)
- OCSL (PT cut), BCIC (PT cut), SLRC (PT cut)
BofA — 3 calls (2 bullish, 1 bearish)
- KLAR (PT raise), FE (PT raise), ENVX (downgrade to Underperform)
Deutsche Bank — 2 calls (1 bullish, 1 bearish)
- KGF (PT raise), IQEPF (PT cut)
Sector Trends
Technology & AI dominated the session, with Nvidia at the center of a multi-firm debate. The overwhelming majority of firms maintained bullish ratings on NVDA, but a notable cluster — Piper Sandler, Jefferies, Wells Fargo, UBS, and Summit Insights — cut price targets or downgraded citing CEO transition uncertainty and longer-term 2027–2028 growth concerns. Microsoft drew uniform bullish reiterations from Guggenheim, TD Cowen, JPMorgan, Piper Sandler, Oppenheimer, and Mizuho following its Ignite conference, signaling strong consensus around its AI platform positioning. The gaming sector also got a boost, with Take-Two Interactive receiving bullish reiterations from BMO, B.Riley, and Oppenheimer ahead of GTA VI.
Consumer & Retail saw a clear split. Walt Disney was the standout winner, with six or more firms raising price targets following an earnings beat — driven by streaming momentum and parks strength. Nike, by contrast, faced a wall of skepticism post-Investor Day: Truist holds a Sell, BMO reiterates Underperform, while BTIG stands as the lone bull with a $50 Buy target. Home Depot received mixed treatment — Truist and Bernstein raised targets on positive comps and share gains, while JPMorgan, Mizuho, and RBC all trimmed on leverage concerns and Q4 guidance caution.
Healthcare & Financials saw selective but significant moves. AbbVie received a major price target raise from Piper Sandler (+$46), Elevance Health was upgraded to Buy by Argus, and Gilead Sciences drew a bullish reiteration from TD Cowen. On the downside, Alnylam took a sharp JPMorgan PT cut (-$115), and the BDC/specialty lending space (Oaktree Specialty Lending, BCP Investment, SLR Investment) saw a sweep of Keefe Bruyette price target reductions on credit quality and NAV concerns. Klarna faced a three-way divergence — BofA raised its target while JPMorgan and Morgan Stanley both cut theirs.
Market Implications
The Nvidia situation is the most telling signal of the session. Despite strong results and guidance, the emergence of CEO transition uncertainty has introduced a new risk premium into the stock, with firms like Piper Sandler and Jefferies cutting targets by $70 each. Yet the bull camp — led by Wedbush at $293, JPMorgan at $230, and Goldman Sachs at $220 — remains intact. The wide dispersion in price targets (from HSBC's $170 Hold to Wedbush's $293 Outperform) reflects genuine uncertainty rather than consensus, which typically signals elevated near-term volatility for the stock.
The Disney earnings beat is generating one of the cleaner consensus shifts of the session — six-plus firms raising targets with no cuts in sight, spanning streaming, parks, and content themes. This kind of broad-based, multi-firm alignment on a single catalyst is a meaningful signal. Contrast that with Nike, where the post-Investor Day reaction is almost uniformly cautious: multiple Hold and Sell reiterations, with only BTIG standing firmly bullish. The market is clearly not yet convinced Nike's turnaround timeline is credible.
For investors, the Klarna divergence is worth watching — BofA sees strong transaction growth warranting a higher target, while JPMorgan and Morgan Stanley are cutting on accounting shifts and financing changes. This kind of three-way split on a recently-public fintech name suggests the market hasn't yet settled on a valuation framework for the stock. Meanwhile, Erste Group's triple downgrade of GE Vernova, Eaton, and Freeport-McMoRan in a single session is an unusually concentrated bearish signal on industrial and materials names that warrants attention.
Key Takeaways
- 🔴 Nvidia (NVDA) — The most-covered stock of the session with 15+ analyst actions; strong results but CEO transition uncertainty is triggering meaningful PT cuts at Piper Sandler (-$70), Jefferies (-$50), Wells Fargo (-$50), and UBS (-$20), even as bulls like Wedbush raise to $293.
- 🟢 Walt Disney (DIS) — Broad consensus PT raise wave post-earnings beat; JPMorgan ($140), Wells Fargo ($140), Rosenblatt ($141), Guggenheim ($135), Needham ($135), Raymond James ($133), and StoneX ($130) all raised targets — one of the cleanest bullish consensus moves of the day.
- 🔴 Nike (NKE) — Post-Investor Day reception is bearish-to-neutral across the board; Truist reiterates Sell ($29), BMO reiterates Underperform ($25), with only BTIG maintaining a Buy ($50) — turnaround skepticism is the dominant narrative.
- 🟢 AbbVie (ABBV) — Piper Sandler's $46 price target raise (to $349 from $303) is one of the largest absolute PT increases of the session, signaling strong conviction in the growth outlook.
- 🔴 Alnylam Pharmaceuticals (ALNY) — JPMorgan's $115 price target cut (to $254 from $369) on revised Amvuttra forecasts is the largest absolute dollar reduction of the session, despite maintaining Overweight.
- 🔴 Enovix (ENVX) — BofA's downgrade to Underperform with a $1 price target on a strategy shift is a severe bearish signal for the battery technology company.
- 🟢 Charles Schwab (SCHW) — Raymond James upgrade to Strong Buy on rate outlook is a high-conviction call worth noting.
- 🟡 Klarna (KLAR) — Three-way analyst divergence (BofA raises, JPMorgan cuts, Morgan Stanley cuts) highlights unresolved valuation uncertainty for the fintech.
- 🔴 Insulet (PODD) — Stifel downgrade to Hold (PT $165) directly conflicts with Jefferies' same-day Buy reiteration at $200 — a notable split on the diabetes device maker.
- 🟢 Elevance Health (ELV) — Argus upgrade to Buy with a $510 target signals improving sentiment on managed care heading into 2027.
- 🔴 Erste Group triple downgrade — GE Vernova (GEV), Eaton (ETN), and Freeport-McMoRan (FCX) all cut to Hold from Buy in a single session — a concentrated bearish signal on industrials and materials.
- 🟢 Tyler Technologies (TYL) — Both TD Cowen (to $475) and Truist (to $500) raised price targets, reflecting strong cloud growth momentum.
- 🟢 Piper Sandler → Instacart (CART) — $15 PT raise to $65 on a DoorDash deal is a significant catalyst-driven move.
- 🔴 Home Depot (HD) — Mixed signals: Truist and Bernstein raised targets while JPMorgan, Mizuho, and RBC all cut — Q4 guidance and leverage concerns are creating a tug-of-war.
- 🔴 Lantern Pharma (LTRN) — Rodman & Renshaw downgrade to Neutral and removal of price target on CEO exit is a sharp negative signal for the small-cap biotech.
Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.
👉 This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/